Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FG 3246

Next Previous
Drug Profile

FG 3246

Alternative Names: Anti-CD46 antibody conjugate - Fortis Therapeutics; Anti-CD46 antibody drug conjugate - Fortis Therapeutics; FG-3246; FOR-46

Latest Information Update: 21 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fortis Therapeutics
  • Developer Fortis Therapeutics; University of California at San Francisco
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer
  • No development reported Multiple myeloma

Most Recent Events

  • 12 May 2025 FibroGen plans a phase II trial in Prostate cancer (Metastatic disease, Hormone refractory, Monotherapy), in 3Q 2025 (NCT06842498)
  • 28 Mar 2025 Updated efficacy and adverse events data from a phase I trial in prostate cancer released by FibroGen
  • 25 Mar 2025 Fibrogen has multiple patents pending for FG 3246 in the USA and other countries

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top